Graybug Vision’s lead program is focused on evaluating the investigational depot formulation of sunitinib, GB-102, for neovascular (wet) age-related macular degeneration (AMD), however, the drug may have therapeutic potential in other vision-threatening diseases such as diabetic macular edema (DME) and retinal vein occlusion (RVO).

To see how GB-102 works, click here.

About Wet AMD

Wet AMD is a common eye condition and a leading cause of vision loss among people age 50 and older.  It causes damage to the macula, a small spot near the center of the retina and the part of the eye needed for sharp, central vision, which allows the ability to see objects that are straight ahead.  Wet AMD can results in severe vision loss and commonly this is treated by a retinal specialist who can inject drugs into the eye to improve vision and slow progression of the disease.  However, in many patients, this requires several injections year to maintain vision in the eye.  GB-102 is an investigational depot formulation of sunitinib, GB-102, with the potential to reduce the need for injections and reduce the burden associated with frequent visits to the clinic for evaluation and treatment.

About DME

DME is a common ocular complication of diabetes and a leading cause of vision loss among people age 50 and younger. DME is caused by excessive leakage of fluid from the small blood vessels in the retina that can lead to swelling of the eye tissues with subsequent loss of vision. Treatment includes optimal medical management (blood glucose control) but in many cases, the retinal specialist will reduce the swelling of the retinal tissue by injecting drugs into the eye. GB-102 is an investigational depot formulation of sunitinib, GB-102, with the potential to reduce the need for injections and reduce the burden associated with frequent visits to the clinic for evaluation and treatment.

About RVO

RVO is a blockage of the blood vessels that drain the normal flow of blood that nourishes the tissues of the retina.  This disruption in blood flow can rapidly “starve” the retina of its blood supply and lead to loss of vision. RVO is the second leading cause of blindness from retinal vascular disease after diabetic eye disease.